This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
HSIC Q3 Earnings Top, Margins Down, Stock Gains in Premarket
by Zacks Equity Research
Henry Schein's third-quarter results reflect an improvement in sales trends in Technology and Value-Added Services business.
Henry Schein (HSIC) Q3 Earnings Top Estimates
by Zacks Equity Research
Henry Schein (HSIC) delivered earnings and revenue surprises of 5.17% and 2.05%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Unlocking Q3 Potential of Henry Schein (HSIC): Exploring Wall Street Estimates for Key Metrics
by Zacks Equity Research
Get a deeper insight into the potential performance of Henry Schein (HSIC) for the quarter ended September 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
Staar Surgical (STAA) Surpasses Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Staar Surgical (STAA) delivered earnings and revenue surprises of 115.79% and 1.59%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
McKesson (MCK) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
McKesson (MCK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Henry Schein (HSIC) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Henry Schein (HSIC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
HSIC Gears Up for Q3 Earnings: Here's What You Need to Know
by Zacks Equity Research
Henry Schein is expected to report impressive sales in both its businesses in the third quarter of 2024, along with a low pace of recovery from the cyber incident.
Why Henry Schein (HSIC) Could Beat Earnings Estimates Again
by Zacks Equity Research
Henry Schein (HSIC) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Henry Schein Stock Gains From Dental Business Expansion Amid Macro Woe
by Zacks Equity Research
Henry Schein strategically sets up distribution centers worldwide to better serve customers and increase its operating efficiency.
HSIC Stock Likely to Get a Boost From New Henry Schein One Launches
by Zacks Equity Research
Henry Schein's dental software arm unveils Dentrix Eligibility offerings to elevate the insurance verification process.
Why Is Henry Schein (HSIC) Up 5.6% Since Last Earnings Report?
by Zacks Equity Research
Henry Schein (HSIC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Henry Schein (HSIC) Hurt by Macroeconomic Woes, Cyber Attacks
by Zacks Equity Research
With sustained macroeconomic pressure, Henry Schein (HSIC) struggles to keep in check its cost of revenues and operating expenses.
Compared to Estimates, Henry Schein (HSIC) Q2 Earnings: A Look at Key Metrics
by Zacks Equity Research
While the top- and bottom-line numbers for Henry Schein (HSIC) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Henry Schein (HSIC) Q2 Earnings Surpass, 2024 Guidance Slashed
by Zacks Equity Research
Henry Schein's (HSIC) second-quarter results reflect an improvement in sales trends in distribution businesses.
Henry Schein (HSIC) Q2 Earnings Beat Estimates
by Zacks Equity Research
Henry Schein (HSIC) delivered earnings and revenue surprises of 0.82% and 4.33%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
The Zacks Analyst Blog Baxter International, Henry Schein and IDEXX Laboratories
by Zacks Equity Research
Baxter International, Henry Schein and IDEXX Laboratories are included in this Analyst Blog.
What's in Store for These 3 MedTech Stocks in Q2 Earnings?
by Urmimala Biswas
MedTech companies' quarterly results are likely to be strong on a sequential basis. Let's see how BAX, HSIC and IDXX are placed ahead of their earnings releases.
Countdown to Henry Schein (HSIC) Q2 Earnings: Wall Street Forecasts for Key Metrics
by Zacks Equity Research
Evaluate the expected performance of Henry Schein (HSIC) for the quarter ended June 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
McKesson (MCK) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
McKesson (MCK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Dentsply International (XRAY) Q2 Earnings and Revenues Lag Estimates
by Zacks Equity Research
Dentsply (XRAY) delivered earnings and revenue surprises of -2% and 1.16%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Henry Schein (HSIC) Q2 Earnings Expected to Decline
by Zacks Equity Research
Henry Schein (HSIC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why Henry Schein (HSIC) is a Strong Momentum Stock
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
How to Play Henry Schein (HSIC) Ahead of Q2 Earnings?
by Zacks Equity Research
Henry Schein (HSIC) is expected to deliver impressive sales in both its businesses in the second quarter of 2024, along with a steady pace of recovery from the cyber incident.
Here's Why Henry Schein (HSIC) is a Strong Value Stock
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Strength Seen in Henry Schein (HSIC): Can Its 5.4% Jump Turn into More Strength?
by Zacks Equity Research
Henry Schein (HSIC) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.